skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 1,524  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Journal Title: Annals Of The Rheumatic Diseases remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Material Type:
Article 		Add to My Research

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Annals of the rheumatic diseases, 2019-06, Vol.78 (6), p.736-745 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2019-215089 ;PMID: 30926722

Full text available

Citations Cited by
2
Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
Material Type:
Article 		Add to My Research

Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states

Annals of the rheumatic diseases, 2018-10, Vol.77 (10), p.1539-1540 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-213184 ;PMID: 29453216

Full text available

Citations Cited by
3
AB0261 Ongoing good response with biologics. data from the austrian biorg registry
AB0261 Ongoing good response with biologics. data from the austrian biorg registry
Material Type:
Article 		Add to My Research

AB0261 Ongoing good response with biologics. data from the austrian biorg registry

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1311 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.7053

Full text available

Citations Cited by
4
AB0281 Reduction rate of rheumatoid factor reflects disease activity of rheumatoid arthritis
AB0281 Reduction rate of rheumatoid factor reflects disease activity of rheumatoid arthritis
Material Type:
Article 		Add to My Research

AB0281 Reduction rate of rheumatoid factor reflects disease activity of rheumatoid arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1320 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.4496

Full text available

Citations Cited by
5
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
Material Type:
Article 		Add to My Research

Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies

Annals of the rheumatic diseases, 2012-09, Vol.71 (9), p.1524-1529 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;2015 INIST-CNRS ;Copyright: 2012 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2011-200726 ;PMID: 22425941 ;CODEN: ARDIAO

Full text available

Citations Cited by
6
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Material Type:
Article 		Add to My Research

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Annals of the rheumatic diseases, 2015-09, Vol.74 (9), p.1706-1713 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2013-205171 ;PMID: 24834926 ;CODEN: ARDIAO

Full text available

Citations Cited by
7
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
Material Type:
Article 		Add to My Research

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Annals of the rheumatic diseases, 2018-02, Vol.77 (2), p.212-220 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 ;Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2018 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-211682 ;PMID: 29066464

Full text available

Citations Cited by
8
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis
Material Type:
Article 		Add to My Research

Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2018-01, Vol.77 (1), p.48-54 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-211735 ;PMID: 28877868

Full text available

Citations Cited by
9
AB0139 VALIDATION AND THE CLINICAL UTILITY OF POLYGENIC RISK SCORING IN ASIAN SLE
AB0139 VALIDATION AND THE CLINICAL UTILITY OF POLYGENIC RISK SCORING IN ASIAN SLE
Material Type:
Article 		Add to My Research

AB0139 VALIDATION AND THE CLINICAL UTILITY OF POLYGENIC RISK SCORING IN ASIAN SLE

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1249-1249 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.5903

Full text available

Citations Cited by
10
A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality
A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality
Material Type:
Article 		Add to My Research

A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality

Annals of the rheumatic diseases, 2017-10, Vol.76 (10), p.1700-1706 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;Copyright: 2017 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2017-211138 ;PMID: 28611082

Full text available

Citations Cited by
11
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Material Type:
Article 		Add to My Research

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Annals of the rheumatic diseases, 2019-11, Vol.78 (11), p.1454-1462 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2019 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2019-215764 ;PMID: 31362993

Full text available

Citations Cited by
12
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)
Material Type:
Article 		Add to My Research

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Annals of the rheumatic diseases, 2016-02, Vol.75 (2), p.382-389 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2014-206008 ;PMID: 25480887 ;CODEN: ARDIAO

Full text available

Citations Cited by
13
Comorbidities in patients with gout prior to and following diagnosis: case-control study
Comorbidities in patients with gout prior to and following diagnosis: case-control study
Material Type:
Article 		Add to My Research

Comorbidities in patients with gout prior to and following diagnosis: case-control study

Annals of the rheumatic diseases, 2016-01, Vol.75 (1), p.210-217 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2015 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2014-206410 ;PMID: 25398375 ;CODEN: ARDIAO

Full text available

Citations Cited by
14
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Material Type:
Article 		Add to My Research

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study

Annals of the rheumatic diseases, 2019-07, Vol.78 (7), p.979-987 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-214816 ;PMID: 30967395

Full text available

Citations Cited by
15
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
Material Type:
Article 		Add to My Research

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study

Annals of the rheumatic diseases, 2016-01, Vol.75 (1), p.45-51 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Copyright: 2015 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2014-206439 ;PMID: 25660991 ;CODEN: ARDIAO

Full text available

Citations Cited by
16
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Material Type:
Article 		Add to My Research

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Annals of the rheumatic diseases, 2017-07, Vol.76 (7), p.1253-1262 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ 2017 ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2016-210457 ;PMID: 28143815

Full text available

Citations Cited by
17
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
Material Type:
Article 		Add to My Research

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

Annals of the rheumatic diseases, 2019-08, Vol.78 (8), p.1048-1054 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-214846 ;PMID: 31088790

Full text available

Citations Cited by
18
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
Material Type:
Article 		Add to My Research

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.47-53 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;2015 INIST-CNRS ;Copyright: 2011 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/ard.2010.138594 ;PMID: 21068095 ;CODEN: ARDIAO

Full text available

Citations Cited by
19
Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis
Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis
Material Type:
Article 		Add to My Research

Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis

Annals of the rheumatic diseases, 2013-12, Vol.72 (12), p.1989-1994 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2013 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2012-202408 ;PMID: 23253927 ;CODEN: ARDIAO

Full text available

Citations Cited by
20
Genetics of rheumatoid arthritis: 2018 status
Genetics of rheumatoid arthritis: 2018 status
Material Type:
Article 		Add to My Research

Genetics of rheumatoid arthritis: 2018 status

Annals of the rheumatic diseases, 2019-04, Vol.78 (4), p.446-453 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;2019 Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-213678 ;PMID: 30530827

Full text available

Citations Cited by

Results 1 - 20 of 1,524  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 2001  (14)
  2. 2001 To 2005  (111)
  3. 2006 To 2010  (142)
  4. 2011 To 2016  (194)
  5. After 2016  (1,064)
  6. More options open sub menu

Resource Type 

  1. Articles  (1,523)
  2. Reviews  (1)
  3. More options open sub menu

Language 

  1. Japanese  (109)
  2. Norwegian  (2)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait